Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia
Friday, July 6, 2012 - 00:00
in Health & Medicine
Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies. The findings of this new clinical study suggest eltrombopag could be a second-line therapeutic option for this disease.